Can I Take Ashwagandha with Jardiance (Empagliflozin)?

Jardiance is the brand name for empagliflozin, an SGLT2 (sodium-glucose cotransporter 2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. Ashwagandha (Withania somnifera) is an herbal supplement, not an FDA-approved drug, most often sold as a root extract standardized to withanolide content. This article covers the specific question of combining the two, not general Jardiance or ashwagandha safety information.

Ashwagandha does not have a pharmacokinetic interaction with empagliflozin documented in the literature reviewed here. Its main biologically plausible effect relevant to a person taking Jardiance is an additive lowering of blood glucose through a separate, cortisol-related mechanism, an effect reported in small clinical trials but not established at the population level for people already on an SGLT2 inhibitor. Anyone combining the two, particularly if also on insulin or a sulfonylurea, should monitor fasting glucose and discuss the combination with their prescriber or pharmacist rather than assume equivalence with either substance alone.

What is established, what is plausible, and what is not

Established: Empagliflozin is FDA-approved and works by blocking renal glucose reabsorption via SGLT2, independent of insulin secretion. It is metabolized mainly through glucuronidation (UGT enzymes) rather than the cytochrome P450 pathway. The empagliflozin prescribing information does not list ashwagandha, or herbal supplements generally, as a documented interaction (verify current label version before relying on this for a specific patient).

Plausible but not proven for this combination: Ashwagandha has been studied in small human trials for effects on fasting glucose, cortisol, and thyroid hormone levels. Several of these trials report reductions in fasting glucose and cortisol over weeks of use. If real, these effects are pharmacologically capable of adding to empagliflozin's glucose-lowering action. No published trial has tested ashwagandha and empagliflozin together, so the size of any additive effect in a real patient is not known.

Not established: Whether ashwagandha meaningfully increases hypoglycemia risk when added to empagliflozin monotherapy, whether dose separation reduces any interaction, and whether ashwagandha's thyroid-stimulating effects interact with SGLT2 inhibitor-related fluid or heart rate changes. These are extrapolations from separate lines of evidence, not direct findings.

Requires verification before clinical reliance: The exact magnitude of glucose and cortisol reduction reported in ashwagandha trials varies across studies and doses; specific percentage figures circulating online should be checked against the primary paper before being used in patient counseling.

How Jardiance works and why ashwagandha does not share its pathway

Empagliflozin blocks SGLT2 in the proximal renal tubule, causing the kidneys to excrete excess glucose in urine rather than reabsorbing it. In the EMPA-REG OUTCOME trial, empagliflozin reduced cardiovascular death in people with type 2 diabetes and established cardiovascular disease compared with placebo (NEJM, Zinman et al. 2015; confirm the specific effect size against the original paper before quoting it, since the exact percentage attributed to this trial varies across secondary sources).

Ashwagandha's withanolide compounds do not act on the SGLT2 transporter. Their studied effects center on the hypothalamic-pituitary-adrenal axis (cortisol regulation) and, in animal and small human studies, possible improvements in insulin sensitivity. Empagliflozin is metabolized largely by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 glucuronidation, with a minor cytochrome P450 contribution, according to its FDA label (verify current label version before relying on this detail). No published data indicate ashwagandha inhibits or induces these UGT enzymes at typical supplement doses. That absence of evidence is not the same as a confirmed absence of effect; it reflects that the specific interaction has not been formally studied.

Could ashwagandha add to Jardiance's blood-sugar-lowering effect?

Several small trials have reported that ashwagandha root extract lowers fasting glucose over weeks of use, with proposed mechanisms including cortisol suppression and improved peripheral insulin sensitivity. Cortisol is a counter-regulatory hormone that raises blood glucose, so a sustained reduction in cortisol is a plausible route to lower fasting glucose readings independent of any diabetes medication.

The American Diabetes Association's Standards of Care describes SGLT2 inhibitor monotherapy as carrying a low intrinsic risk of hypoglycemia on its own, and recommends closer monitoring when other glucose-lowering influences are added to a regimen (ADA Standards of Care, current issue; confirm current-year edition, since Standards of Care are republished annually). Ashwagandha, if its reported glucose-lowering effect holds in an individual, would count as such an added influence, particularly for someone whose HbA1c is already near target on empagliflozin alone, or who also takes insulin or a sulfonylurea.

For someone on empagliflozin as their only glucose-lowering medication, the absolute hypoglycemia risk from adding ashwagandha is likely to remain low based on the modest effect sizes reported in available trials, but it is not zero, and it has not been directly measured in this combination.

Thyroid considerations

Small clinical studies have reported that ashwagandha can raise thyroid hormone levels (T3 and T4) in some adults, particularly those with subclinical hypothyroidism at baseline. This is relevant to a Jardiance user for an indirect reason: SGLT2 inhibitors already produce mild osmotic diuresis, and a shift toward higher thyroid hormone activity independently raises heart rate and metabolic rate. A person who starts ashwagandha and experiences a thyroid hormone shift could notice increased urination, mild dehydration, or lightheadedness that overlaps with known empagliflozin side effects, making the cause harder to identify without labs. No published data describe this overlap directly in patients taking both substances; the concern is a reasoned extrapolation, not a documented clinical pattern.

A published case report has described thyrotoxicosis developing in a patient who added high-dose ashwagandha to a levothyroxine regimen. This describes a drug-supplement interaction (levothyroxine, not empagliflozin) and should not be read as evidence about SGLT2 inhibitors specifically; it is included here because it illustrates that ashwagandha's thyroid effects can be clinically significant in some individuals, and anyone with known thyroid disease should treat that risk as separate from, and in addition to, the glucose question.

Practical steps if you are considering or already using both

Before starting: Get baseline fasting glucose and, if you have any thyroid history, a TSH and free T4. Tell your prescriber or pharmacist that you are adding ashwagandha, and confirm your current empagliflozin regimen and any other glucose-lowering medications.

Timing: There is no dedicated dose-separation study for this pair. A common general precaution for supplements with uncertain absorption interactions is to separate dosing by a few hours; taking empagliflozin with breakfast as labeled, and ashwagandha at a different time of day such as with lunch, is a reasonable convention rather than a proven requirement.

Monitoring in the first weeks: Check fasting glucose with a home glucometer periodically and watch for symptoms of low blood sugar (shakiness, sweating, confusion, unusual fatigue). If you have thyroid risk factors, recheck thyroid labs several weeks after starting.

Ongoing: If glucose and, where relevant, thyroid values remain stable and no hypoglycemia symptoms occur, continued combined use appears tolerated for that individual, though this is not the same as a guarantee of long-term safety, which has not been studied for this specific pairing.

Before surgery: Ashwagandha's cortisol-suppressing effect is a reason some clinicians advise stopping it in advance of a planned procedure, since blunted cortisol response can affect the body's stress response during surgery. Confirm timing with the surgical or anesthesia team rather than assuming a fixed interval.

Who should be more cautious about this combination

• People on multiple glucose-lowering medications (for example empagliflozin plus a sulfonylurea, or plus insulin): adding a substance with an independent, if modest, glucose-lowering effect raises hypoglycemia risk more than in someone on empagliflozin alone.
• People with autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease): ashwagandha's effect on thyroid hormone production is unpredictable in this population and has been linked to a reported case of thyrotoxicosis when combined with thyroid medication; specialist input is reasonable before use.
• People with adrenal insufficiency: ashwagandha's cortisol-suppressing action is a theoretical concern for anyone with reduced adrenal reserve, and this population should not start ashwagandha without endocrinology input.

None of these represent an absolute contraindication documented on the empagliflozin label; they reflect a cautious extrapolation from ashwagandha's known pharmacology.

If you are already taking both without problems

Tolerating the combination so far is meaningful information. Bring both medications and supplements to your next visit, confirm fasting glucose and, if relevant, thyroid labs are within range, and mention the combination explicitly so it is documented in your chart. If you notice new symptoms since starting ashwagandha, such as urination beyond your usual Jardiance pattern, lightheadedness on standing, tremor, palpitations, or unexplained low glucose readings, stop the ashwagandha and contact your clinician rather than adjusting your Jardiance dose yourself.

Evidence-status interaction assessment

What a clinician or pharmacist should verify before advising a specific patient: current empagliflozin label language on supplement interactions, the patient's full glucose-lowering regimen (to assess additive hypoglycemia risk), any personal or family thyroid history, and the specific ashwagandha product's labeled dose and standardization, since formulations vary widely and are not FDA-regulated for potency or purity.

Bottom line

No documented pharmacokinetic interaction exists between ashwagandha and empagliflozin. The realistic concern is additive glucose lowering and, in some individuals, thyroid hormone shifts, both plausible from each substance's independent pharmacology but not directly studied together. Monitor fasting glucose after starting either substance in the presence of the other, treat multiple glucose-lowering medications or thyroid disease as reasons for closer supervision, and confirm any specific numeric claims about effect size against the original trial before relying on them for a treatment decision.